Sphere Medical’s Proxima blood analyser meets primary endpoint

25 November 2011 (Last Updated November 25th, 2011 03:30)

Sphere Medical's Proxima Generation 2 has met its primary endpoint in a multicentre clinical trial conducted at two UK hospitals, Queen Elizabeth Hospital Birmingham and West Suffolk Hospital.

Sphere Medical's Proxima Generation 2 has met its primary endpoint in a multicentre clinical trial conducted at two UK hospitals, Queen Elizabeth Hospital Birmingham and West Suffolk Hospital.

The Proxima system is an arterial blood analyser based on Sphere Medical's proprietary microanalyser platform technology.

The primary endpoint of the study has evaluated the similar performance to laboratory and point-of-care blood-gas analysers, measuring arterial blood in a clinical setting.

The device provides real-time analysis of a patient's arterial blood with laboratory accuracy.

Output data being displayed on a bedside monitor.

The company claims that the Proxima blood analyser can be useable for repeated blood measurements without a deterioration in performance.

Sphere Medical CEO Stuart Hendry said the Proxima will deliver rapid and convenient measurement of blood chemistry in a critical care setting.